Product
FTX-6058
Aliases
FTX-6058/placebo oral capsule(s)
2 clinical trials
3 indications
Indication
Sickle Cell DiseaseIndication
Sickle Cell AnemiaIndication
Adult HealthClinical trial
A Phase 1 Open-Label, Multiple-Dose Study to Evaluate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of FTX-6058 in Subjects With Sickle Cell Disease (SCD)Status: Recruiting, Estimated PCD: 2025-04-01
Clinical trial
A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Single-and Multiple-Dose Study Evaluating Safety, Tolerability, and Pharmacokinetics, With an Open-Label Initial Food Effect and CYP3A Drug-Drug Interaction Study, of FTX-6058 in Healthy Adult Subjects, and a Randomized, Double-Blind, Placebo-Controlled Multiple-Dose Study Evaluating, Safety, Tolerability and Pharmacokinetics in Subjects With Sickle Cell Disease (SCD)Status: Completed, Estimated PCD: 2022-11-15